# Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors

> **NCT06621563** · PHASE1 · RECRUITING · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 780 (estimated)

## Conditions studied

- Solid Tumors
- Non-Small Cell Lung Cancer
- Colorectal Cancer

## Interventions

- **DRUG:** HS-20117 combined HS-20093
- **DRUG:** HS-20117 combined Platinum-containing chemotherapy
- **DRUG:** HS-20117 combined HS-20093 and 5-FU
- **DRUG:** HS-20117+CAPEOX
- **DRUG:** HS-20117+FOLFIRI
- **DRUG:** HS-20117+mFOLFOX6

## Key facts

- **NCT ID:** NCT06621563
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-14
- **Primary completion:** 2026-03-30
- **Final completion:** 2026-12-01
- **Target enrollment:** 780 (ESTIMATED)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06621563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06621563, "Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06621563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*